Discover open access scientific publications

Search, annotate, share and cite publications

Publications by S Clisant

A Dose-Escalating Phase I of Imatinib Mesylate With Fixed Dose of Metronomic Cyclophosphamide in Targeted Olid Tumours

British Journal of Cancer

Cancer Research

Oncology

2013

English

Related publications

A Multi-Arm Phase I Dose Escalating Study of an Oral NOTCH Inhibitor BMS-986115 in Patients With Advanced Solid Tumours

Investigational New Drugs

Oncology

Pharmacology

2018

English

A Phase II Study to Evaluate Lenalidomide in Combination With Metronomic-Dose Cyclophosphamide in Patients With Heavily Pretreated Classical Hodgkin Lymphoma

English

P1.01-91 a Phase I Study of Fixed Dose Vinorelbine and Escalating Doses of Ifosfamide in First-Line Advanced Non-Small Cell Lung Cancer

Journal of Thoracic Oncology

English

Phase I Clinical Trial Combining Imatinib Mesylate and IL-2

English

Result of High-Dose Imatinib Mesylate in Patients With Philadelphia Chromosome--Positive Chronic Myeloid Leukemia After Failure of Interferon-

English

Clinical Benefit in Phase-I Trials of Novel Molecularly Targeted Agents: Does Dose Matter?

British Journal of Cancer

Cancer Research

Oncology

2009

English

Randomized Phase II Trial of Letrozole and Letrozole Plus Low-Dose Metronomic Oral Cyclophosphamide as Primary Systemic Treatment in Elderly Breast Cancer Patients

Journal of Clinical Oncology

English

A Swine Model of Selective Geographic Atrophy of Outer Retinal Layers Mimicking Atrophic AMD: A Phase I Escalating Dose of Subretinal Sodium Iodate

Investigative Ophthalmology and Visual Science

Molecular Neuroscience

English

Development of a Subcutaneous Fixed-Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose-Finding Study

Journal of Clinical Pharmacology

Pharmacology

2018

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by S Clisant

A Dose-Escalating Phase I of Imatinib Mesylate With Fixed Dose of Metronomic Cyclophosphamide in Targeted Olid Tumours

Related publications

A Multi-Arm Phase I Dose Escalating Study of an Oral NOTCH Inhibitor BMS-986115 in Patients With Advanced Solid Tumours

A Phase II Study to Evaluate Lenalidomide in Combination With Metronomic-Dose Cyclophosphamide in Patients With Heavily Pretreated Classical Hodgkin Lymphoma

P1.01-91 a Phase I Study of Fixed Dose Vinorelbine and Escalating Doses of Ifosfamide in First-Line Advanced Non-Small Cell Lung Cancer

Phase I Clinical Trial Combining Imatinib Mesylate and IL-2

Result of High-Dose Imatinib Mesylate in Patients With Philadelphia Chromosome--Positive Chronic Myeloid Leukemia After Failure of Interferon-

Clinical Benefit in Phase-I Trials of Novel Molecularly Targeted Agents: Does Dose Matter?

Randomized Phase II Trial of Letrozole and Letrozole Plus Low-Dose Metronomic Oral Cyclophosphamide as Primary Systemic Treatment in Elderly Breast Cancer Patients

A Swine Model of Selective Geographic Atrophy of Outer Retinal Layers Mimicking Atrophic AMD: A Phase I Escalating Dose of Subretinal Sodium Iodate

Development of a Subcutaneous Fixed-Dose Combination of Pertuzumab and Trastuzumab: Results From the Phase Ib Dose-Finding Study